| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.19▼ | 1.20▼ | 1.20▼ | 1.18▼ | 1.20▼ |
| MA10 | 1.19▼ | 1.18▼ | 1.18▼ | 1.19▼ | 1.31▼ |
| MA20 | 1.17▲ | 1.19▼ | 1.19▼ | 1.19▼ | 1.16▲ |
| MA50 | 1.18▼ | 1.20▼ | 1.20▼ | 1.35▼ | 1.57▼ |
| MA100 | 1.24▼ | 1.26▼ | 1.28▼ | 1.13▲ | 7.76▼ |
| MA200 | 1.32▼ | 1.43▼ | 1.36▼ | 1.54▼ | 1,268.31▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.001▲ | 0.003▲ | 0.003▲ | 0.005▲ | 0.098▲ |
| RSI | 49.825▼ | 48.958▼ | 48.831▼ | 45.900▼ | 43.150▼ |
| STOCH | 42.407 | 63.106 | 58.939 | 61.688 | 33.635 |
| WILL %R | -54.545 | -54.545 | -58.333 | -50.000 | -62.162 |
| CCI | -13.605 | -12.500 | -26.848 | 8.887 | -24.396 |
|
Monday, April 06, 2026 06:29 AM
SAN DIEGO, CA / ACCESS Newswire / April 6, 2026 /Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to ...
|
|
Monday, March 30, 2026 01:54 PM
A majority of CKD patients present with cellular inflammation and immunoparalysis predose --Gemini durably normalizes ...
|
|
Tuesday, March 24, 2026 03:00 PM
SAN DIEGO, CA / ACCESS Newswire / March 24, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 10/04/26 | 1.23 | 1.245 | 1.14 | 1.17 | 94,006 |
| 09/04/26 | 1.22 | 1.28 | 1.185 | 1.23 | 62,481 |
| 08/04/26 | 1.15 | 1.27 | 1.13 | 1.21 | 110,452 |
| 07/04/26 | 1.15 | 1.165 | 1.10 | 1.13 | 35,736 |
| 06/04/26 | 1.20 | 1.225 | 1.12 | 1.16 | 134,194 |
| 02/04/26 | 1.2001 | 1.25 | 1.20 | 1.25 | 52,807 |
| 01/04/26 | 1.23 | 1.23 | 1.18 | 1.23 | 42,377 |
| 31/03/26 | 1.22 | 1.27 | 1.18 | 1.20 | 113,168 |
| 30/03/26 | 1.12 | 1.22 | 1.06 | 1.19 | 207,060 |
| 27/03/26 | 1.13 | 1.168 | 1.1101 | 1.13 | 32,946 |
|
|
||||
|
|
||||
|
|